Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

FHS
July 11, 2023
11:31 am

NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, today announced it has been awarded £1.6M in grant funding from Innovate UK’s New Cancer Therapeutics program.

LSD Anxiety Win; Pimavanserin Schizophrenia Flop; ‘Bright Light’ for Depression?

In a phase IIb study, a single dose of an investigational LSD-containing drug (MM120) led to significantly greater reductions in 12-week scores on the Hamilton

March 14, 2024

CDC and social media: The new misinformation war

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

February 6, 2024

The Hidden Cybersecurity Risk: Implanted Medical Devices

Andrew Spier, Vice President of Advanced Cyber Solutions and Commercial Services at Core4ce Recent and high-profile cyber, ransomware and supply chain attacks on Kaiser Permanente,

December 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.